New drug aims to stop esophageal cancer recurrence in post-surgery patients
NCT ID NCT07266480
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug adebrelizumab can help prevent esophageal cancer from returning after surgery. About 142 adults who had their cancer completely removed will receive either adebrelizumab or a placebo. The main goal is to see how long patients stay cancer-free, and researchers will also monitor side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS OESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
12, Jiankang road, Chang'an District, Shijiazhuang, Hebei 050000, China
RECRUITINGShijiazhuang, Hebei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.